Results 221 to 230 of about 95,563 (285)

Advancing the Therapeutic Frontier in Thyroid Eye Disease. [PDF]

touchREV Endocrinol
Mohammadi SO, Ray C.
europepmc   +1 more source

Long-term Outcome After Correction of Lower Eyelid Retraction With Donor Sclera in Thyroid Eye Disease. [PDF]

Plast Reconstr Surg Glob Open
Halsøy K, Hope AM, Foshaug C, Lysebo DE, Rødahl E, Ueland HO.   +5 more
europepmc   +1 more source

A preliminary study developing a scoring model incorporating fibrinogen-like protein 2 for predicting glucocorticoid resistance in thyroid eye disease. [PDF]

Thyroid Res
Matsuzawa K, Izawa S, Kadowaki K, Fukaya K, Matsumoto K, Nagata K, Okura T, Fujii S, Miyazaki D, Taniguchi SI, Yamamoto K, Imamura T.   +11 more
europepmc   +1 more source

Incidence and risk factors of tocilizumab-induced hypofibrinogenemia in patients with thyroid eye disease: a single-center retrospective study. [PDF]

Front Endocrinol (Lausanne)
Wang E, Hu Q, Xu S, Zhou J, Wang J, Song Z, Wang X.   +6 more
europepmc   +1 more source

Light Discomfort Thresholds in Patients with Moderate-to-Severe Active versus Mild Non-Active Thyroid Eye Disease. [PDF]

Clin Ophthalmol
Lixi F, Corrias S, Coco G, Lai R, Corda C, Cuccu A, Vitiello L, Troisi M, Mura C, Boi F, Lanzolla G, Giannaccare G.   +11 more
europepmc   +1 more source

Role of concurrent intravenous pulse steroids and orbital radiation in the management of thyroid eye disease.

Oman J Ophthalmol
Poonam NS, Alam MS, Barh A, Balasundaram V, Mukherjee B.   +4 more
europepmc   +1 more source

Human Papillomavirus and Thyroid Eye Disease.

JAMA Ophthalmol
Garg I, Meyer BI, Gallo RA, Wester ST, Pelaez D.   +4 more
europepmc   +1 more source